Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohn's perianal fistulas

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1825-1834

  Tozer, Phil ^a,b   Ng, Siew C ^a,d   Siddiqui, Muhammed R ^a,b   Plamondon, Sophie ^a   Burling, David ^a,b   Gupta, Arun ^a   Swatton, Anna ^a   Tripoli, Sherrill ^a   Vaizey, Carolynne J ^a,b   Kamm, Michael A ^a,b,c   Phillips, Robin ^a,b   Hart, Ailsa ^a,b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

anal fistula; Anti TNF drugs; Crohn's disease; MRI

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CIPROFLOXACIN; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALING; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIANAL ABSCESS; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERINEUM; PROGNOSIS; PROSPECTIVE STUDIES; RECTAL FISTULA; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84866391090     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21940     Document Type: Article

References (29)

1. Ardizzone S, Porro GB,. Perianal Crohn's disease: overview. Dig Liver Dis. 2007; 39: 957-958. (Pubitemid 47354990)
2. Tang LY, Rawsthorne P, Bernstein CN,. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol. 2006; 4: 1130-1134. (Pubitemid 44311656)
3. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656. (Pubitemid 43374514)
4. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998; 114: 1151-1160. (Pubitemid 28243900)
5. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008; 103: 3082-3093.
6. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995; 123: 132-142.
7. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009; 15: 17-24.
8. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003; 125: 380-388. (Pubitemid 36929418)
9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885. (Pubitemid 38252535)
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65. (Pubitemid 46108762)
11. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128: 862-869. (Pubitemid 40523539)
12. Domenech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther. 2005; 22: 1107-1113. (Pubitemid 41779518)
13. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol. 2009; 104: 2973-2986.
14. Van AG, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003; 98: 332-339. (Pubitemid 36232382)
15. Rasul I, Wilson SR, MacRae H, et al. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol. 2004; 99: 82-88. (Pubitemid 38679106)
16. Schwartz DA, White CM, Wise PE, et al. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas. Inflamm Bowel Dis. 2005; 11: 727-732. (Pubitemid 41271176)
17. Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn's fistulas. Aliment Pharmacol Ther. 2011; 33: 5-22.
18. Regueiro M, Mardini H,. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003; 9: 98-103. (Pubitemid 36367318)
19. Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007; 50: 1754-1760. (Pubitemid 350077116)
20. Talbot C, Sagar PM, Johnston MJ, et al. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis. 2005; 7: 164-168. (Pubitemid 40352646)
21. Guidi L, Ratto C, Semeraro S, et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol. 2008; 12: 111-117.
22. Topstad DR, Panaccione R, Heine JA, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum. 2003; 46: 577-583. (Pubitemid 36576412)
23. Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging. Clin Gastroenterol Hepatol. 2010.
24. Savoye-Collet C, Savoye G, Koning E, et al. Fistulizing perianal Crohn's disease: Contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis. 2010.
25. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003; 17 Suppl 2: 11-17. (Pubitemid 36831453)
26. Vermeire S, Van AG, Rutgeerts P,. Perianal Crohn's disease: classification and clinical evaluation. Dig Liver Dis. 2007; 39: 959-962. (Pubitemid 47354984)
27. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther. 2003; 17: 1145-1151. (Pubitemid 36605751)
28. Louis E, Vernier-Massouille G, Grimaud J, ea. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136: A-146.
29. Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther. 2009; 30: 757-766.